Abstract：Objective: To investigate the therapeutic effect of compound anisodine on non-proliferative diabetic retinopathy, and to provide reference for its application. Methods: According to simple random sampling and manual stratification, 146 patients with non-proliferative diabetic retinopathy admitted to the First Affiliated Hospital of Xi'an Medical College from September 2018 to September 2020 were divided into 2 groups, with 73 cases in each group. The control group was treated with total retinal laser photocoagulation (PRP)+ conventional treatment, and the observation group was treated with compound camphorine, comparison before and after treatment clinical signs (hemorrhage, edema disappeared and effusion absorption time), fundus index [vision, bleeding area, seepage area, number of micro hemangioma, within the scope of 30 o view the average sensitivity threshold (MS), retinal oscillation potential total amplitude values (oPs)], vascular endothelial growth factor (VEGF) and insulin-like growth factor number one (IGF 1) level change and clinical curative effect. Results: After treatment, the total effective rate of observation group (95.89%) was higher than that of control group (75.34%)(χ2=18.048, P=0.000). The bleeding absorption time, edema disappearance time and exudation absorption time in the observation group were significantly shorter than those in the control group, while the bleeding area and exudation area were also smaller than those in the control group (P<0.05). In terms of the difference before and after treatment, the increase in visual acuity, MS, and oPs total wave amplitude difference in the observation group was significantly greater than that in the control group (P<0.05), and the reduction of microangioma was significantly greater than that in the control group (P<0.05). The observation group had significantly greater reductions in VEGF and IGF-1 than the control group (P<0.05). Conclusion: Compound anisodine can effectively improve the clinical symptoms of patients with non-proliferative diabetic retinopathy, regulate the levels of vascular endothelial growth factor and insulin-like growth factor 1, and promote ocular microcirculation.
王芬芬, 马卫国, 殷小红, 谢传庆, 乔瑛, 燕洁静, 曹燕. 复方樟柳碱注射液对非增生性糖尿病视网膜病变VEGF IGF-1的影响[J]. 河北医学, 2021, 27(10): 1622-1625.
WANG Fenfen, MA Weiguo, YIN Xiaohong, et al. Effect of Compound Anisodine Hydrobromide Injection on VEGF and IGF-1 in Patients with Non Proliferative Diabetic Retinopathy. HeBei Med, 2021, 27(10): 1622-1625.
[1] Aslan H E,Sukru Beydemir.Phenolic compounds:the inhibition effect on polyol pathway enzymes[J].Chem-Biol Interact,2017,266(25):47~55. [2] 陆静毅,马晓静,周健,等.持续葡萄糖监测测定的目标范围内时间与2型糖尿病视网膜病变的相关性研究[J].中华内科杂志,2019,58(1):65. [3] E.Graham-Rowe,F.Lorencatto,J.G.Lawrenson,et al.Barriers to and enablers of diabetic retinopathy screening attendance:a systematic review of published and grey literature[J].Diabetic Med,2018,35(10):1308~1319. [4] He H,Yu M,Lu L,et al.Electroretinogram evaluation for the treatment of proliferative diabetic retinopathy by short-pulse pattern scanning laser panretinal photocoagulation[J].Laser Med Sci,2018,33(5):1095~1102. [5] 张雷,赵芳.复方樟柳碱两种不同使用方式治疗非增生性糖尿病视网膜病变的疗效[J].中华实验眼科杂志,2018,36(12):970~972. [6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):34~86. [7] C.P Wilkinson,Frederick L Ferris III,Ronald E Klein,et al.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J].Ophthalmology,2003,110(9):1667~1682. [8] Ronald C.W.Ma.Epidemiology of diabetes and diabetic complications in China[J].Diabetologia,2018,61(Suppl 1):1~12. [9] 郭龙,黄昭昭.糖尿病视网膜病变患者PRP术后预后的相关影响因素[J].国际眼科杂志,2019,19(7):1225~1227. [10] 韩嵩.非增殖期糖尿病性视网膜病变采用复方樟柳碱治疗的临床价值评估[J].中国医药指南,2018,16(16):121~122. [11] Sorayya Kheirouri,Siamak Naghizadeh,Mohammad Alizadeh.Zinc supplementation does not influence serum levels of VEGF,BDNF,and NGF in diabetic retinopathy patients:a randomized controlled clinical trial[J].Nutr Neurosci,2018,22(10):1~7.
2021, Vol. 27 
冀公网安备13080202000677号